Florensocatib

CAS 2762114-61-2

MF C23H23FN4O4 MW438.5 g/mol

(2S)-N-[(1S)-1-cyano-2-[2-fluoro-4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide

(2S)-N-{(1S)-1-cyano-2-[2-fluoro-4-(3-methyl-2-oxo-2,3-dihydro1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-
carboxamide
cathepsin inhibitor, HSK 31858, CHF 10196, DPP1-IN-1, RWC743JRK7

Florensocatib (originally designated as HSK31858 or CHF10196) is an investigative, highly potent, oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1). It is being actively researched for its ability to reduce the frequency of pulmonary exacerbations in adults suffering from inflammatory respiratory diseases like bronchiectasis

Mechanism of Action

DPP1 (also known as cathepsin C) is a lysosomal protease enzyme responsible for activating neutrophil serine proteases (NSPs). In conditions like non-cystic fibrosis bronchiectasis, hyperactive neutrophils accumulate in the airways, causing severe tissue damage, chronic inflammation, and airway widening.

By inhibiting DPP1, florensocatib prevents the activation of these damaging enzymes, effectively targeting the primary driver of neutrophilic inflammation in the lungs.

Clinical Development & Trial Progress

Florensocatib is undergoing global evaluation across multiple advanced clinical trials:

• The SAVE-BE Trial: An earlier clinical phase where the drug demonstrated high potency and favorable efficacy profiles in treating inflammatory lung conditions.
• The HOPE-BE Trial: A definitive Phase III protocol launched to evaluate the long-term safety and overall reduction of pulmonary exacerbation frequencies specifically among Chinese adults.
• Global Phase III Status: According to records on ClinicalTrials.gov, randomised, double-blind trials are evaluating the drug against a placebo in participants aged 12 to 85 for treatment windows stretching up to 78 weeks.

SYN

US11807635,

https://patentscope.wipo.int/search/en/detail.jsf?docId=US395653715&_cid=P21-MPKKTA-33002-1

Example 1: (S)—N—((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide (Compound 1)

Step 4: (S)—N—((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide (Compound 1)

1D (0.32 g, 0.59 mmol) was dissolved in formic acid (2.5 mL) and upon completion of the addition, the mixture was reacted at 50° C. for 10 min. The reaction solution was concentrated to dryness and ethyl acetate (20 mL) was added. Then saturated aqueous sodium bicarbonate solution was added dropwise to adjust the pH to about 8. The organic layer was separated and the remaining aqueous layer was extracted with ethyl acetate (25 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by silica gel column chromatography (dichloromethane:methanol (v/v)=20:1) to obtain the title compound 1 (0.15 g, 58.0%). LC-MS (ESI): m/z=439.1 [M+H] +.

1H NMR (400 MHz, CDCl 3) δ 7.43-7.22 (m, 5H), 7.12 (d, 1H), 5.19 (dd, 1H), 4.18-4.04 (m, 1H), 4.05-3.95 (m, 1H), 3.78 (m, 1H), 3.46 (s, 3H), 3.41-3.17 (m, 3H), 3.03-2.87 (m, 3H), 1.88 (m, 2H).

SYN

US11807635,

https://patentscope.wipo.int/search/en/detail.jsf?docId=US395653715&_cid=P21-MPKKYT-35548-1

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022042591&_cid=P21-MPKKS9-32509-1

(S)-N-((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide(compound 1)

Step 4: (S)-N-((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazacycloheptane-2-carboxamide (Compound 1) 

[0360]

(S)-N-((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide(compound 1)

[0361]1D (0.32 g, 0.59 mmol) was dissolved in formic acid (2.5 mL), and the mixture was reacted at 50 °C for 10 min after the addition was complete. The solution was concentrated to dryness, and ethyl acetate (20 mL) was added. The pH was adjusted to approximately 8 by dropwise addition of saturated sodium bicarbonate solution. The organic layer was separated and extracted with ethyl acetate (25 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane:methanol (v/v) = 20:1) to give title compound 1 (0.15 g, 58.0%). LC-MS (ESI): m/z = 439.1 [M+H] ⁺ . 

[0362]

¹H NMR(400MHz,CDCl ₃)δ7.43–7.22(m,5H),7.12(d,1H),5.19(dd,1H),4.18–4.04(m,1H),4.05–3.95(m,1H),3.78(m,1H),3.46(s,3H),3.41–3.17(m,3H),3.03–2.87(m,3H),1.88(m,2H).

ADVT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

• Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereofPublication Number: US-2023121807-A1Priority Date: 2020-08-26
• Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereofPublication Number: WO-2022042591-A1Priority Date: 2020-08-26
• Nitrile derivative as dipeptidyl peptidase 1 inhibitor and application thereofPublication Number: CN-115996923-APriority Date: 2020-08-26
• Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereofPublication Number: EP-4129989-A1Priority Date: 2020-08-26
• Dipeptidyl peptidase 1 inhibitor polymorph and preparation method and application thereofPublication Number: CN-118696040-APriority Date: 2022-02-22
• Salt and crystal form of dipeptidyl peptidase inhibitor compoundPublication Number: EP-4484414-A1Priority Date: 2022-02-22
• Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereofPublication Number: US-11807635-B2Priority Date: 2020-08-26Grant Date: 2023-11-07
• A kind of nitrile derivative as dipeptidyl peptidase 1 inhibitor and use thereofPublication Number: TW-202214616-APriority Date: 2020-08-26
• Nitrile derivatives acting as inhibitors of dipeptidyl peptidase 1 and uses thereofPublication Number: KR-20230084134-APriority Date: 2020-08-26
• Salt and crystal form of dipeptidyl peptidase inhibitor compoundPublication Number: WO-2023160542-A1Priority Date: 2022-02-22
• Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use thereforPublication Number: WO-2023160579-A1Priority Date: 2022-02-22
• Salts and crystalline forms of dipeptidyl peptidase inhibitor compoundsPublication Number: CN-118660873-APriority Date: 2022-02-22
• Preparation method of nitrogen-containing heterocyclic compoundPublication Number: WO-2023160541-A1Priority Date: 2022-02-22
• Preparation method of nitrogen-containing heterocyclic compoundPublication Number: CN-118742547-APriority Date: 2022-02-22
• Dipeptidyl peptidase 1 inhibitors and uses thereofPublication Number: WO-2025059526-A1Priority Date: 2023-09-15
• Pharmaceutical composition containing dipeptidyl peptidase small molecule inhibitorPublication Number: WO-2024193695-A1Priority Date: 2023-03-23
• Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitorsPublication Number: WO-2024173556-A2Priority Date: 2023-02-15
• Novel dpp1 inhibitors and uses thereofPublication Number: WO-2024026433-A2Priority Date: 2022-07-28
• Novel dpp1 inhibitors and uses thereofPublication Number: EP-4561565-A2Priority Date: 2022-07-28

/////////florensocatib, anax labs, cathepsin inhibitor, HSK 31858, CHF 10196, DPP1-IN-1, RWC743JRK7